+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Diabetic Retinopathy Market Size, Share & Trends Analysis Report By Type (Proliferative DR, Non-proliferative DR), By Management (Anti-VEGF Therapy, Vitrectomy), And Segment Forecasts, 2024 - 2030

  • PDF Icon

    Report

  • 120 Pages
  • February 2024
  • Region: Global
  • Grand View Research
  • ID: 4479737
Description Jump to:
The global diabetic retinopathy market size is expected to reach USD 13.77 billion by 2030, registering a CAGR of 6.43% from 2024 to 2030. The rising prevalence of diabetes, growing geriatric population, and increasing prevalence of blindness due to diabetes are the major factors anticipated to boost market growth over the forecast period. Growth in the market is further propelled by the increasing awareness about diabetes management & care and new product launches. Diabetic retinopathy is caused by damage to the blood vessels in the retina, which leads to blurred vision and vision loss in most cases.

The increase in prevalence of diabetes due to aging, obesity, and unhealthy lifestyles is contributing to the growth of the market. Obesity is a major factor leading to diabetes. According to WHO, in 2021, around 39% of adults aged 18 years and above were overweight, and 13% were obese worldwide. In addition to obesity, diabetes is becoming increasingly prevalent globally. The International Diabetes Federation (IDF) estimated l537 million adults (aged 20 to 79 years) were living with diabetes in 2021, which is expected to rise to 642 million by 2040. The IDF also reports that the prevalence of diabetes is increasing globally, with the highest increases witnessed in low- and middle-income countries. In 2021, the regions with the highest number of adults living with diabetes were the Western Pacific (167 million), South Asia (88 million), and Europe (59 million).

The rising geriatric population is a significant driver of the diabetes epidemic, as diabetes in older people is directly linked with higher mortality and reduced functional status. According to WHO, 80% of older people are expected to live in low- and middle-income nations by 2050. The population is aging at a considerably higher rate than in the past. In 2020, the number of persons aged 60 years and more will outnumber children under the age of 5 years. Between 2015 and 2050, the proportion of the global population aged over 60 years will nearly double, from 12% to 22%.

Diabetic Retinopathy Market Report Highlights

  • Non-proliferative diabetic retinopathy accounted for the largest share, by type, in 2023. The presence of large number of patients within the bracket of less than 10 years of diabetic history contributed to the large size of this segment.
  • Anti-VEGF segment accounted for the largest share, by management, in 2023. High applicability of these drugs in treatment of early diagnosis and mild to moderate cases of non-proliferative DR treatment is among the prime factors leading to segmental growth.
  • The Asia Pacific market is expected to grow with the highest CAGR over the forecast period. Large population base in this region, high prevalence of diabetes, and rising geriatric population are likely to bolster the market.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Management
1.2.3. Regional scope
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. Internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Type outlook
2.2.2. Management outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Diabetic Retinopathy Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of diabetes
3.2.1.2. Growing geriatric population
3.2.1.3. Increasing prevalence of blindness due to diabetes
3.2.2. Market restraint analysis
3.2.2.1. Lack of accurate diagnosis
3.2.2.2. Adverse effect on treatment
3.3. Diabetic Retinopathy Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Environmental landscape
3.3.2.6. Legal landscape
Chapter 4. Diabetic Retinopathy Market: Type Estimates & Trend Analysis
4.1. Type Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. Global Diabetic Retinopathy Market by Type Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Proliferative Diabetic Retinopathy
4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Non-proliferative Diabetic Retinopathy
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Diabetic Retinopathy Market: Management Estimates & Trend Analysis
5.1. Management Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. Global Diabetic Retinopathy Market by Management Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Anti-VEGF
5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Intraocular Steroid Injection
5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3. Laser Surgery
5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.4. Vitrectomy
5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Diabetic Retinopathy Market: Regional Estimates & Trend Analysis
6.1. Regional Market Share Analysis, 2023 & 2030
6.2. Regional Market Dashboard
6.3. Global Regional Market Snapshot
6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
6.5. North America
6.5.1. U.S.
6.5.1.1. Key country dynamics
6.5.1.2. Regulatory framework/ reimbursement structure
6.5.1.3. Competitive scenario
6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
6.5.2. Canada
6.5.2.1. Key country dynamics
6.5.2.2. Regulatory framework/ reimbursement structure
6.5.2.3. Competitive scenario
6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Europe
6.6.1. UK
6.6.1.1. Key country dynamics
6.6.1.2. Regulatory framework/ reimbursement structure
6.6.1.3. Competitive scenario
6.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
6.6.2. Germany
6.6.2.1. Key country dynamics
6.6.2.2. Regulatory framework/ reimbursement structure
6.6.2.3. Competitive scenario
6.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
6.6.3. France
6.6.3.1. Key country dynamics
6.6.3.2. Regulatory framework/ reimbursement structure
6.6.3.3. Competitive scenario
6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
6.6.4. Italy
6.6.4.1. Key country dynamics
6.6.4.2. Regulatory framework/ reimbursement structure
6.6.4.3. Competitive scenario
6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
6.6.5. Spain
6.6.5.1. Key country dynamics
6.6.5.2. Regulatory framework/ reimbursement structure
6.6.5.3. Competitive scenario
6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
6.6.6. Norway
6.6.6.1. Key country dynamics
6.6.6.2. Regulatory framework/ reimbursement structure
6.6.6.3. Competitive scenario
6.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
6.6.7. Sweden
6.6.7.1. Key country dynamics
6.6.7.2. Regulatory framework/ reimbursement structure
6.6.7.3. Competitive scenario
6.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
6.6.8. Denmark
6.6.8.1. Key country dynamics
6.6.8.2. Regulatory framework/ reimbursement structure
6.6.8.3. Competitive scenario
6.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
6.7. Asia Pacific
6.7.1. Japan
6.7.1.1. Key country dynamics
6.7.1.2. Regulatory framework/ reimbursement structure
6.7.1.3. Competitive scenario
6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
6.7.2. China
6.7.2.1. Key country dynamics
6.7.2.2. Regulatory framework/ reimbursement structure
6.7.2.3. Competitive scenario
6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
6.7.3. India
6.7.3.1. Key country dynamics
6.7.3.2. Regulatory framework/ reimbursement structure
6.7.3.3. Competitive scenario
6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
6.7.4. Australia
6.7.4.1. Key country dynamics
6.7.4.2. Regulatory framework/ reimbursement structure
6.7.4.3. Competitive scenario
6.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
6.7.5. South Korea
6.7.5.1. Key country dynamics
6.7.5.2. Regulatory framework/ reimbursement structure
6.7.5.3. Competitive scenario
6.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
6.7.6. Thailand
6.7.6.1. Key country dynamics
6.7.6.2. Regulatory framework/ reimbursement structure
6.7.6.3. Competitive scenario
6.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
6.8. Latin America
6.8.1. Brazil
6.8.1.1. Key country dynamics
6.8.1.2. Regulatory framework/ reimbursement structure
6.8.1.3. Competitive scenario
6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
6.8.2. Mexico
6.8.2.1. Key country dynamics
6.8.2.2. Regulatory framework/ reimbursement structure
6.8.2.3. Competitive scenario
6.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
6.8.3. Argentina
6.8.3.1. Key country dynamics
6.8.3.2. Regulatory framework/ reimbursement structure
6.8.3.3. Competitive scenario
6.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
6.9. MEA
6.9.1. South Africa
6.9.1.1. Key country dynamics
6.9.1.2. Regulatory framework/ reimbursement structure
6.9.1.3. Competitive scenario
6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
6.9.2. Saudi Arabia
6.9.2.1. Key country dynamics
6.9.2.2. Regulatory framework/ reimbursement structure
6.9.2.3. Competitive scenario
6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
6.9.3. UAE
6.9.3.1. Key country dynamics
6.9.3.2. Regulatory framework/ reimbursement structure
6.9.3.3. Competitive scenario
6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
6.9.4. Kuwait
6.9.4.1. Key country dynamics
6.9.4.2. Regulatory framework/ reimbursement structure
6.9.4.3. Competitive scenario
6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. List of key distributors and channel partners
7.3.2. Key customers
7.3.3. Key company market share analysis, 2023
7.3.4. Bayer AG
7.3.4.1. Company overview
7.3.4.2. Financial performance
7.3.4.3. Product benchmarking
7.3.4.4. Strategic initiatives
7.3.5. ABBVIE INC.
7.3.5.1. Company overview
7.3.5.2. Financial performance
7.3.5.3. Product benchmarking
7.3.5.4. Strategic initiatives
7.3.6. Novartis AG
7.3.6.1. Company overview
7.3.6.2. Financial performance
7.3.6.3. Product benchmarking
7.3.6.4. Strategic initiatives
7.3.7. Oxurion NV
7.3.7.1. Company overview
7.3.7.2. Financial performance
7.3.7.3. Product benchmarking
7.3.7.4. Strategic initiatives
7.3.8. Sirnaomics
7.3.8.1. Company overview
7.3.8.2. Financial performance
7.3.8.3. Product benchmarking
7.3.8.4. Strategic initiatives
7.3.9. Alimera Sciences
7.3.9.1. Company overview
7.3.9.2. Financial performance
7.3.9.3. Product benchmarking
7.3.9.4. Strategic initiatives
7.3.10. Ampio Pharmaceuticals Inc.
7.3.10.1. Company overview
7.3.10.2. Financial performance
7.3.10.3. Product benchmarking
7.3.10.4. Strategic initiatives
7.3.11. BCNPeptides
7.3.11.1. Company overview
7.3.11.2. Financial performance
7.3.11.3. Product benchmarking
7.3.11.4. Strategic initiatives
7.3.12. Kowa Company Ltd.
7.3.12.1. Company overview
7.3.12.2. Financial performance
7.3.12.3. Product benchmarking
7.3.12.4. Strategic initiatives
7.3.13. Genentech, Inc.
7.3.13.1. Company overview
7.3.13.2. Financial performance
7.3.13.3. Product benchmarking
7.3.13.4. Strategic initiatives
List of Tables
Table 1 List of Abbreviation
Table 2 North America diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 3 North America diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 4 North America diabetic retinopathy market, by region, 2018 - 2030 (USD Million)
Table 5 U.S. diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 6 U.S. diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 7 Canada diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 8 Canada diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 9 Europe diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 10 Europe diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 11 Europe diabetic retinopathy market, by region, 2018 - 2030 (USD Million)
Table 12 Germany diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 13 Germany diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 14 UK diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 15 UK diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 16 France diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 17 France diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 18 Italy diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 19 Italy diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 20 Spain diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 21 Spain diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 22 Denmark diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 23 Denmark diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 24 Sweden diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 25 Sweden diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 26 Norway diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 27 Norway diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 28 APAC diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 29 APAC diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 30 APAC diabetic retinopathy market, by region, 2018 - 2030 (USD Million)
Table 31 Japan diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 32 Japan diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 33 China diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 34 China diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 35 India diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 36 India diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 37 South Korea diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 38 South Korea diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 39 Thailand diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 40 Thailand diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 41 Australia diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 42 Australia diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 43 Latin America diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 44 Latin America diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 45 Latin America diabetic retinopathy market, by region, 2018 - 2030 (USD Million)
Table 46 Brazil diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 47 Brazil diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 48 Mexico diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 49 Mexico diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 50 Argentina diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 51 Argentina diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 52 Middle East and Africa diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 53 Middle East and Africa diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 54 Middle East and Africa diabetic retinopathy market, by region, 2018 - 2030 (USD Million)
Table 55 Saudi Arabia diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 56 Saudi Arabia diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 57 South Africa diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 58 South Africa diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 59 UAE diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 60 UAE diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
Table 61 Kuwait diabetic retinopathy market, by type, 2018 - 2030 (USD Million)
Table 62 Kuwait diabetic retinopathy market, by management, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in North America
Fig. 5 Primary interviews in Europe
Fig. 6 Primary interviews in APAC
Fig. 7 Primary interviews in Latin America
Fig. 8 Primary interviews in MEA
Fig. 9 Market research approaches
Fig. 10 Value-chain-based sizing & forecasting
Fig. 11 QFD modeling for market share assessment
Fig. 12 Market formulation & validation
Fig. 13 Diabetic retinopathy market: Market outlook
Fig. 14 Diabetic retinopathy market competitive insights
Fig. 15 Parent market outlook
Fig. 16 Related/ancillary market outlook
Fig. 17 Penetration and growth prospect mapping
Fig. 18 Industry value chain analysis
Fig. 19 Diabetic retinopathy market driver impact
Fig. 20 Diabetic retinopathy market restraint impact
Fig. 21 Diabetic retinopathy market: type movement analysis
Fig. 22 Diabetic retinopathy market: type outlook and key takeaways
Fig. 23 Proliferative diabetic retinopathy market estimates and forecast, 2018 - 2030
Fig. 24 Non-proliferative diabetic retinopathy market estimates and forecast, 2018 - 2030
Fig. 25 Diabetic retinopathy market: management movement analysis
Fig. 26 Diabetic retinopathy market: management outlook and key takeaways
Fig. 27 Anti-VEGF market estimates and forecast, 2018 - 2030
Fig. 28 Intraocular Steroid Injection market estimates and forecast, 2018 - 2030
Fig. 29 Laser Surgery market estimates and forecast, 2018 - 2030
Fig. 30 Vitrectomy market estimates and forecast, 2018 - 2030
Fig. 31 Global Diabetic retinopathy market: regional movement analysis
Fig. 32 Global Diabetic retinopathy market: regional outlook and key takeaways
Fig. 33 North America
Fig. 34 North America market estimates and forecast, 2018 - 2030
Fig. 35 U.S.
Fig. 36 U.S. market estimates and forecast, 2018 - 2030
Fig. 37 Canada
Fig. 38 Canada market estimates and forecast, 2018 - 2030
Fig. 39 Europe
Fig. 40 Europe. market estimates and forecast, 2018 - 2030
Fig. 41 UK
Fig. 42 UK market estimates and forecast, 2018 - 2030
Fig. 43 Germany
Fig. 44 Germany market estimates and forecast, 2018 - 2030
Fig. 45 France
Fig. 46 France market estimates and forecast, 2018 - 2030
Fig. 47 Italy
Fig. 48 Italy market estimates and forecast, 2018 - 2030
Fig. 49 Spain
Fig. 50 Spain market estimates and forecast, 2018 - 2030
Fig. 51 Denmark
Fig. 52 Denmark market estimates and forecast, 2018 - 2030
Fig. 53 Sweden
Fig. 54 Sweden market estimates and forecast, 2018 - 2030
Fig. 55 Norway
Fig. 56 Norway market estimates and forecast, 2018 - 2030
Fig. 57 Asia Pacific
Fig. 58 Asia Pacific market estimates and forecast, 2018 - 2030
Fig. 59 Japan
Fig. 60 Japan market estimates and forecast, 2018 - 2030
Fig. 61 China
Fig. 62 China market estimates and forecast, 2018 - 2030
Fig. 63 India
Fig. 64 India market estimates and forecast, 2018 - 2030
Fig. 65 South Korea
Fig. 66 South Korea market estimates and forecast, 2018 - 2030
Fig. 67 Thailand
Fig. 68 Thailand market estimates and forecast, 2018 - 2030
Fig. 69 Australia
Fig. 70 Australia market estimates and forecast, 2018 - 2030
Fig. 71 Latin America
Fig. 72 Latin America market estimates and forecast, 2018 - 2030
Fig. 73 Brazil
Fig. 74 Brazil market estimates and forecast, 2018 - 2030
Fig. 75 Mexico
Fig. 76 Mexico market estimates and forecast, 2018 - 2030
Fig. 77 Argentina
Fig. 78 Argentina market estimates and forecast, 2018 - 2030
Fig. 79 Middle East and Africa
Fig. 80 Middle East and Africa. market estimates and forecast, 2018 - 2030
Fig. 81 Saudi Arabia
Fig. 82 Saudi Arabia market estimates and forecast, 2018 - 2030
Fig. 83 South Africa
Fig. 84 South Africa market estimates and forecast, 2018 - 2030
Fig. 85 UAE
Fig. 86 UAE market estimates and forecast, 2018 - 2030
Fig. 87 Kuwait
Fig. 88 Kuwait market estimates and forecast, 2018 - 2030
Fig. 89 Participant categorization- Diabetic retinopathy market
Fig. 90 Market share of key market players- Diabetic retinopathy market

Companies Mentioned

  • Bayer AG
  • ABBVIE INC.
  • Novartis AG
  • Oxurion NV
  • Sirnaomics
  • Alimera Sciences
  • Ampio Pharmaceuticals Inc.
  • BCNPeptides
  • Kowa Company Ltd.
  • Genentech, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages120
PublishedFebruary 2024
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 8.9 Billion
Forecasted Market Value ( USD ) by 2030 $ 13.77 Billion
Compound Annual Growth Rate6.4%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Retinal Laser Photocoagulation Market Size, Share & Trends Analysis Report By Laser Type (Diode Laser, Green Laser), By Indication (Proliferative Diabetic Retinopathy), By Modality, By End-use, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Retinal Laser Photocoagulation Market Size, Share & Trends Analysis Report By Laser Type (Diode Laser, Green Laser), By Indication (Proliferative Diabetic Retinopathy), By Modality, By End-use, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 130 Pages
  • Global
From
Diabetic Retinopathy Market by Type, Management - Global Forecast 2025-2030 - Product Image

Diabetic Retinopathy Market by Type, Management - Global Forecast 2025-2030

  • Report
  • 186 Pages
  • Global
From
Global Non-Proliferative Diabetic Retinopathy Market Report 2024 - Product Image

Global Non-Proliferative Diabetic Retinopathy Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Proliferative Diabetic Retinopathy (PDR) Global Market Report 2024 - Product Image

Proliferative Diabetic Retinopathy (PDR) Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Diabetic Retinopathy Market Report by Type, Treatment Type, End-User, and Region 2024-2032 - Product Image

Diabetic Retinopathy Market Report by Type, Treatment Type, End-User, and Region 2024-2032

  • Report
  • 139 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.